Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Bevacizumab 56Cetuximab 50Fluorouracil 45Leucovorin 39Oxaliplatin 38pembrolizumab 31Specimen Handling 27Irinotecan 25Magnetic Resonance Spectroscopy 17Biopsy 17Nivolumab 15HMPL-013 13Folfox protocol 13Capecitabine 13Gemcitabine 12Cisplatin 12trifluridine tipiracil drug combination 11Panitumumab 11Carboplatin 11Pemetrexed 9IFL protocol 9encorafenib 8balstilimab 8Standard of Care 8Paclitaxel 8Early Intervention, Educational 8130-nm albumin-bound paclitaxel 8fludarabine 7atezolizumab 7Educational Status 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × aflibercept × 90 days × Clear all
NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
59 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡